Lophora is a drug-development start-up developing new rapid-acting drugs for central nervous system diseases including treatment-resistant depression.
Lophora
The company are focusing on innovative rapid-acting drugs made for central nervous system diseases, including treatment-resistant depression (TRD). They plan to begin their first human trials by 2022.
Founded in 2018 Lophora has successfully finished the initial characterization of its lead candidate through funding ($2 million) granted by the BioInovation institute (Novo Nordisk Foundation) and plan to begin first-in-human trials by 2022.
In April 2020, the company raised $1.48 million during an Incubation round.
Key Staff
- Bo Tandrup – CEO
News
- Lophora: The new, next generation psychedelic drug to replace psilocybin? (Psychedelic Invest, December 2020)
Activities
B2B
Biotech
Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates